论文部分内容阅读
据瑞典研究人员报告,绝经期后的早期乳癌病人用他莫昔芬治疗5年与治疗2年相比,似乎使冠心病死亡率减少30%以上。这些结果源于对瑞典乳癌组织进行的一项杰出研究的继续随访。瑞典东南肿瘤中心负责人诺登斯科尔德及其同事曾于1996年报告,与治疗2年相比,他莫昔芬治疗5年可以改善绝经期后早期乳癌病人的存活率。经过对4175名女性再随访5年,研究者们发现,在他莫昔芬治疗2年的女性患者中,381人死于乳癌以外的其他原因,而治疗5年的只有307人。
Swedish researchers report that treatment of early breast cancer patients with tamoxifen for five years after menopause appears to reduce coronary deaths by more than 30% compared with two years of treatment. These results stem from the follow-up of a distinguished study of Swedish breast cancer. Nordenskold and his colleagues, head of the Swedish Southeast Oncology Center, reported in 1996 that tamoxifen treatment for five years improved survival in patients with early-stage breast cancer after menopause compared with two-year treatment. After a further 5 years of 4175 women, the researchers found that 381 of the female patients who had been on tamoxifen for 2 years died of something other than breast cancer, compared with 307 for 5 years.